CANF: Longer-than-expected survival in liver cancer and narrowed net loss mark H1 2026 results
Longer-than-expected survival in the pivotal liver cancer study and durable outcomes in pancreatic cancer highlight clinical progress. Net loss narrowed to $4.60 million for H1 2026, with stable revenues and increased R&D spending. Interim analysis for the psoriasis study is expected in Q1 2027.Ori…